Corti makes its clinical-AI platform available to startups as Europe's regulatory legislation increases.

      The Copenhagen-based company has announced that its Symphony model has surpassed OpenAI on HealthBench Professional, while also providing credits and regulatory assistance to founders developing healthcare AI globally. Corti, the clinical AI firm located in Copenhagen, has introduced a no-equity accelerator aimed at healthcare and life sciences startups, making its Symphony model stack available to founders worldwide amidst a time when the regulatory costs for creating medical AI in Europe are at unprecedented levels.

      On Tuesday, the company shared that Symphony, its primary clinical-grade model, has outperformed OpenAI on HealthBench Professional, the standard for realistic clinician interactions that OpenAI launched last month with its ChatGPT for Clinicians product. The new Startup Acceleration Program offers up to $5,000 in credits for the complete Symphony stack, which includes agents, medical coding, speech-to-text, and text generation, and, according to the company, is trained on over 1.5 million hours of clinical audio.

      Participants in the program will have direct access to Corti’s clinical and regulatory team regarding the EU AI Act, MDR, and data-residency queries, along with founder-led roadmap webinars and invitations to Corti events in cities such as New York, Copenhagen, London, and Berlin. Applications are being accepted on a rolling basis with a one-week response time. There is no need for a pitch process or equity participation, and the program is available for companies ranging from pre-seed to Series B in healthcare, clinical workflows, or related life sciences.

      The launch occurs against a tightening regulatory backdrop. In April, OpenAI provided free clinical AI access to all verified healthcare professionals in the U.S. A week later, OpenEvidence, a clinical AI search platform valued at $12 billion and utilized by approximately 40% of U.S. physicians on a daily basis, retracted from the UK and EU due to regulatory uncertainties stemming from the EU AI Act. The high-risk system regulations associated with that withdrawal will become effective on August 2, 2026, although AI integrated within CE-marked medical devices that fall under the MDR or IVDR will follow a different timeline set to begin on August 2, 2027.

      Corti argues that the regulatory costs in Europe are a significant barrier, noting that attaining EU MDR certification costs founders between €200,000 and €600,000 per device and takes about 12 to 18 months, according to industry guides. An analysis by Galen Growth for Q1 2026 indicates that European digital health funding is consolidating in larger, later-stage rounds, with investors showing a preference for companies that can demonstrate clinical evidence and integrated workflows over mere performance metrics.

      Andreas Cleve, co-founder and chief executive of Corti, stated, “The future of healthcare AI won’t be built by one company. It will be built by thousands of teams, each possessing extensive knowledge of specific care settings, workflows, or patient demographics. Our role is to provide those builders with a head start: the leading clinical AI model, the supporting evidence, and a clear path to production that we've already navigated for regulated health systems, allowing them to concentrate on what they do best—the workflow, the patient population, the challenges they truly understand.”

      Aisel Health, a European startup dedicated to psychiatric workflows, is among the development teams currently utilizing Corti. Co-founder and CEO Augusta Klingsten Peytz remarked, “Psychiatrists are a scarce and highly specialized resource. Their focus should be solely on clinical decisions; everything else is extraneous. Currently, the majority of a psychiatrist’s time is consumed not by clinical decision-making but by administrative and repetitive tasks surrounding it. By leveraging Corti, we at Aisel can concentrate on creating specialized psychiatric workflows that enable clinicians to regain their capacity instead of reconstructing the clinical-grade foundation beneath them.”

      To date, Corti has raised $100 million, with offices located in Copenhagen, New York, and London. The release of Symphony for Medical Coding in April claimed a 25% accuracy advantage over OpenAI and Anthropic on ACI-BENCH and MDACE, two academic medical coding benchmarks, and the company asserts that the stack supports AI for systems serving over 100 million patients annually, including the NHS. Corti positions the program as a means to leverage the very conditions that challenge horizontal model providers in Europe to benefit vertical clinical-AI players. Applications are now open.